Rayno Dx and Tools Portfolio: CSII HOLX ILMN TMO Stellar Performers

Solid  earnings reports-All of Our Picks Are Strong Holds But Strong Dollar a Factor in 2105 Cardiovascular Systems (CSII) Stock Soars 15% On Strong Revenues Interventional treatments for cardiovascular disease Q2 Revenues soared 38% to $44.7M compared to previous fiscal Q2 2014. Fiscal Q2 2105 loss was $5.3M or (0.17) per share. Hologic (HOLX) Beats […]

Continue Reading 0

Biotech Stocks Are Apparently Immune to Risks of the Day: New Highs Again …Update 2

3:55 p FEDspeak confuses markets with S&P down 1.25% Too much money around too little yield=deflation concerns. Energy takes a big hit again down 4%. Biotechs off 2% and more. ——— Update 1/28 Technology outperforming biotech in mid-day trading AAPL and semiconductor stocks are leading the NASDAQ up today. Speculators in mid-cap biotech stocks are […]

Continue Reading 0

Rayno Life Science Stocks: Stealth Rally- CLVS, GILD, PCYC.. Update-1

1/27 Sell-Off Likely Today –Durable Goods Decreased 3.4% In December Green Screen In Biotech Despite Flat Market- Mid-Day Trading 12:45 p 1/26 Most Rayno Life Science stocks were up today in a mixed market where energy is the leading sector. XBI New High at 204.21 FBT up 1.5% to $111>New high at 111.38 XLV up […]

Continue Reading 0

MO Players Take Profits Again in Biotech-Risk Off: AGIO, BLUE, JUNO, PBYI, KITE, ZIOP

NASDAQ at 4667  up 0.27%     XBI at $194.4 down 2.88% Clinical Stage Immuno-oncology Stocks Hit Hard Again Momentum traders took money off the table for the second time in three days. Most large cap biopharmaceutical stocks were in the red but down less than 1 % except Alexion (ALXN) down 2%.The Rayno Mid-Cap […]

Continue Reading 0

JPMorgan Healthcare Conference Notes #4: Next Gen Sequencing (NGS)

Seminar: Harnessing the Power of Next Gen Sequencing: The View from Industry 1/12/15 A panel of leading entrepreneurial R&D executives presented their outlook and issues on the future of Next Gen Sequencing (NGS), focusing on drug development and future clinical diagnostic applications. The panel was Randy Scott Ph.D. Founder and CEO of Invitae, George Yancopoulos […]

Continue Reading 0